| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Leicester, UK
Correspondence to:
Correspondence to:
Dr C E Brightling
Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Groby Road, Leicester LE3 9QP, UK; ceb17{at}le.ac.uk
Background: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD). Whether the response to inhaled corticosteroids is related to the presence of eosinophilic inflammation is unclear.
Methods: A randomised, double blind, crossover trial of placebo and mometasone furoate (800 µg/day), each given for 6 weeks with a 4 week washout period, was performed in subjects with COPD treated with bronchodilator therapy only. Spirometric tests, symptom scores, chronic respiratory disease questionnaire (CRQ), and induced sputum were performed before and after each treatment phase.
Results: Ninety five patients were recruited of which 60 were randomised. Overall there were no treatment associated changes in forced expiratory volume in 1 second (FEV1), total CRQ, or sputum characteristics. After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV1 increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile. The mean change in post-bronchodilator FEV1 with mometasone compared with placebo in the highest tertile was 0.11 l (95% CI 0.03 to 0.19). This improvement was not associated with a fall in the sputum eosinophil count.
Conclusions: An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV1 following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRQ, Chronic Respiratory Disease Questionnaire; ECP, eosinophilic cationic protein; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IL-8, interleukin 8; SOB, shortness of breath; TCC, total cell count; VAS, visual analogue score
Keywords: chronic obstructive pulmonary disease; sputum eosinophilia; inhaled corticosteroids; mometasone
Relevant Article
Thorax 2005 60: 175a.
This article has been cited by other articles:
|
|
 |
|
  R. D. Gray, G. MacGregor, D. Noble, M. Imrie, M. Dewar, A. C. Boyd, J. A. Innes, D. J. Porteous, and A. P. Greening Sputum Proteomics in Inflammatory and Suppurative Respiratory Diseases Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. L. Borrill, K. Roy, and D. Singh Exhaled breath condensate biomarkers in COPD Eur. Respir. J., August 1, 2008; 32(2): 472 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. E. K. Pogson, T. M. McKeever, and A. Fogarty The association between serum osmolality and lung function among adults Eur. Respir. J., July 1, 2008; 32(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Kunisaki, K. L. Rice, E. N. Janoff, T. S. Rector, and D. E. Niewoehner Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: A prospective study Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 55 - 64. [Abstract] [PDF]
|
|
|
|
|
|
G. Braganza, R. Chaudhuri, and N. C. Thomson Review: Treating patients with respiratory disease who smoke Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 95 - 107. [Abstract] [PDF]
|
|
|
|
|
|
J. Vestbo, W. Anderson, H. O. Coxson, C. Crim, F. Dawber, L. Edwards, G. Hagan, K. Knobil, D. A. Lomas, W. MacNee, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) Eur. Respir. J., April 1, 2008; 31(4): 869 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Snoeck-Stroband, T. S. Lapperre, M. M. E. Gosman, H. M. Boezen, W. Timens, N. H. T. ten Hacken, J. K. Sont, P. J. Sterk, P. S. Hiemstra, and the Groningen Leiden Universities Corticosteroids Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies Eur. Respir. J., January 1, 2008; 31(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Siva, R. H. Green, C. E. Brightling, M. Shelley, B. Hargadon, S. McKenna, W. Monteiro, M. Berry, D. Parker, A. J. Wardlaw, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Eur. Respir. J., May 1, 2007; 29(5): 906 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M Turino Emphysema in COPD: consequences and causes. Thorax, December 1, 2006; 61(12): 1031 - 1036. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Leigh, M. M. M. Pizzichini, M. M. Morris, F. Maltais, F. E. Hargreave, and E. Pizzichini Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Eur. Respir. J., May 1, 2006; 27(5): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Brightling Clinical Applications of Induced Sputum Chest, May 1, 2006; 129(5): 1344 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R O'Donnell, D Breen, S Wilson, and R Djukanovic Inflammatory cells in the airways in COPD Thorax, May 1, 2006; 61(5): 448 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Saha, R. Siva, C. E. Brightling, and I. D. Pavord COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. Eur. Respir. J., April 1, 2006; 27(4): 863 - 865. [Full Text] [PDF]
|
|
|
|
|
|
N. C. Barnes, Y.-S. Qiu, I. D. Pavord, D. Parker, P. A. Davis, J. Zhu, M. Johnson, N. C. Thomson, P. K. Jeffery, and on behalf of the SCO30005 Study Group Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
